|
ES2248581T3
(es)
|
2001-03-12 |
2006-03-16 |
Intercept Pharmaceuticals, Inc. |
Esteroides como agonistas de fxr.
|
|
PL1734970T3
(pl)
|
2004-03-12 |
2015-05-29 |
Intercept Pharmaceuticals Inc |
Leczenie zwłóknienia z zastosowaniem ligandów FXR
|
|
US10987362B2
(en)
|
2004-03-12 |
2021-04-27 |
Intercept Pharmaceuticals, Inc. |
Treatment of fibrosis using FXR ligands
|
|
ITMI20050912A1
(it)
|
2005-05-19 |
2006-11-20 |
Erregierre Spa |
Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
|
|
US7932244B2
(en)
|
2006-06-27 |
2011-04-26 |
Intercept Pharmaceuticals, Inc. |
Bile acid derivatives as FXR ligands for the prevention or treatment of FXR-mediated diseases or conditions
|
|
KR101555716B1
(ko)
|
2007-01-19 |
2015-09-25 |
인터셉트 파마슈티컬즈, 인크. |
Ｔｇｒ5 조절제로서의 23-치환 담즙산 및 이의 사용 방법
|
|
EP2025674A1
(de)
|
2007-08-15 |
2009-02-18 |
sanofi-aventis |
Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
|
WO2010014836A2
(en)
*
|
2008-07-30 |
2010-02-04 |
Intercept Pharmaceuticals, Inc. |
Tgr5 modulators and methods of use thereof
|
|
DK2698375T3
(en)
|
2008-11-19 |
2018-05-28 |
Intercept Pharmaceuticals Inc |
TGR5 modulators and methods for using them
|
|
CA2744817C
(en)
|
2008-11-26 |
2020-07-07 |
Satiogen Pharmaceuticals, Inc. |
Bile acid recycling inhibitors for treatment of obesity and diabetes
|
|
JP2012509892A
(ja)
|
2008-11-26 |
2012-04-26 |
サティオゲン ファーマシューティカルズ，インク． |
サティオゲン類を含有する組成物及び使用の方法
|
|
EP2379081B1
(en)
|
2008-12-19 |
2013-03-20 |
Royal College of Surgeons in Ireland |
Treatment of diarrhoea
|
|
WO2011107494A1
(de)
|
2010-03-03 |
2011-09-09 |
Sanofi |
Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
|
|
US9719068B2
(en)
|
2010-05-06 |
2017-08-01 |
Children's Hospital Medical Center |
Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
|
|
EP2575821B1
(en)
|
2010-05-26 |
2015-08-12 |
Satiogen Pharmaceuticals, Inc. |
Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
|
|
ITRM20100329A1
(it)
*
|
2010-06-15 |
2011-12-16 |
Franco Baldelli |
Modulazione del recettore nucleare per i farnesoidi (fxr) con molecole agoniste per la prevenzione e trattamento di fenomeni aterosclerotici indotti da somministrazione di inibitori delle proteasi
|
|
WO2011157827A1
(de)
|
2010-06-18 |
2011-12-22 |
Sanofi |
Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
|
|
EP2525223A1
(en)
*
|
2011-05-19 |
2012-11-21 |
Universiteit Maastricht |
In vitro method for predicting in vivo genotoxicity of chemical compounds.
|
|
EP2545964A1
(en)
|
2011-07-13 |
2013-01-16 |
Phenex Pharmaceuticals AG |
Novel FXR (NR1H4) binding and activity modulating compounds
|
|
US11154559B2
(en)
|
2011-09-29 |
2021-10-26 |
Ethicon Endo-Surgery, Inc. |
Methods and compositions of bile acids
|
|
CN104023727B
(zh)
|
2011-10-28 |
2017-04-05 |
鲁美纳医药公司 |
用于治疗小儿胆汁淤积性肝病的胆汁酸再循环抑制剂
|
|
CA2852957C
(en)
|
2011-10-28 |
2020-08-04 |
Lumena Pharmaceuticals, Inc. |
Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease
|
|
US9982008B2
(en)
|
2012-06-19 |
2018-05-29 |
Intercept Pharmaceuticals, Inc. |
Preparation and uses of obeticholic acid
|
|
SI3336097T1
(sl)
|
2012-06-19 |
2021-07-30 |
Intercept Pharmaceuticals, Inc. |
Priprava nekristalinične oblike obetiholne kisline
|
|
SG11201503247UA
(en)
*
|
2012-10-26 |
2015-06-29 |
Intercept Pharmaceuticals Inc |
Process for preparing bile acid derivatives
|
|
AU2013352288B2
(en)
*
|
2012-11-28 |
2017-11-23 |
Intercept Pharmaceuticals, Inc. |
Treatment of pulmonary disease
|
|
TN2015000497A1
(en)
*
|
2013-05-14 |
2017-04-06 |
Intercept Pharmaceuticals Inc |
11-hydroxyl-derivatives of bile acids and amino acid conjugates thereof as farnesoid x receptor modulators
|
|
WO2014200349A1
(en)
|
2013-06-13 |
2014-12-18 |
Fast Forward Pharmaceutical B.V. |
Cd40 signalling inhibitor and a further compound, wherein the further compound is a bile acid, a bile acid derivative, an tgr5-receptor agonist, an fxr agonist or a combination thereof, for the treatment of chronic inflammation, and the prevention of gastrointestinal cancer or fibrosis.
|
|
BR112016002268B1
(pt)
*
|
2013-08-01 |
2022-11-01 |
The Penn State Research Foundation |
Uso de inibidores do receptor x farnesoide
|
|
DK3043865T3
(da)
*
|
2013-09-11 |
2021-02-01 |
Univ Claude Bernard Lyon |
Fremgangsmåder og farmaceutiske sammensætningr til behandlingen af hepatitis b-virusinfektion
|
|
MX356006B
(es)
*
|
2013-10-18 |
2018-04-24 |
Centro De Investig Y Asistencia En Tecnologia Y Diseno Del Estado De Jalisco A C |
Proceso para obtener una molécula que sirve como elicitor de péptidos antimicrobianos.
|
|
CA3236835A1
(en)
|
2013-11-22 |
2015-05-28 |
Mina Therapeutics Limited |
C/ebp alpha short activating rna compositions and methods of use
|
|
CN106661548B
(zh)
|
2014-05-28 |
2020-12-11 |
儿童医院医疗中心 |
用于经由定向分化将前体细胞转化为胃组织的方法和系统
|
|
SMT202000070T1
(it)
*
|
2014-05-29 |
2020-03-13 |
Bar Pharmaceuticals S R L |
Derivati del colano per l'uso del trattamento e/o la prevenzione di malattie mediate da fxr e tgr5/gpbar1
|
|
EP3197448B1
(en)
|
2014-09-24 |
2019-04-24 |
Gilead Sciences, Inc. |
Methods of treating liver disease
|
|
CN106459136B
(zh)
*
|
2014-09-28 |
2018-06-26 |
江苏盛迪医药有限公司 |
一种奥贝胆酸的制备方法
|
|
JP6804438B2
(ja)
|
2014-10-17 |
2020-12-23 |
チルドレンズ ホスピタル メディカル センター |
多能性幹細胞を使用するヒト小腸のｉｎ ｖｉｖｏモデル、並びにそれを作製、及び使用する方法
|
|
SG11201703717SA
(en)
*
|
2014-11-06 |
2017-06-29 |
Enanta Pharm Inc |
Bile acid analogs an fxr/tgr5 agonists and methods of use thereof
|
|
EA033445B1
(ru)
|
2014-11-19 |
2019-10-31 |
Nzp Uk Ltd |
5-бета-6-алкил-7-гидрокси-3-оновые стероиды в качестве промежуточных соединений для получения стероидных модуляторов fxr
|
|
KR102546748B1
(ko)
|
2014-11-19 |
2023-06-22 |
엔제트피 유케이 리미티드 |
스테로이드 FXR 조절인자를 제조하기 위한 중간체로서의 6α-알킬-3,7-다이온 스테로이드
|
|
KR102527821B1
(ko)
|
2014-11-19 |
2023-05-02 |
엔제트피 유케이 리미티드 |
스테로이드 FXR 조절인자를 제조하기 위한 중간체로서의 6α-알킬-6,7-다이온 스테로이드
|
|
CN107207559B
(zh)
|
2014-11-19 |
2019-10-25 |
Nzp英国有限公司 |
作为制备类固醇fxr调节剂的中间体的6-烷基-7-羟基-4-烯-3-酮类固醇
|
|
US11578097B2
(en)
|
2014-11-26 |
2023-02-14 |
Enanta Pharmaceuticals, Inc. |
Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof
|
|
US10208081B2
(en)
|
2014-11-26 |
2019-02-19 |
Enanta Pharmaceuticals, Inc. |
Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
|
|
EP3223823A4
(en)
|
2014-11-26 |
2018-10-17 |
Enanta Pharmaceuticals, Inc. |
Bile acid analogs as fxr/tgr5 agonists and methods of use thereof
|
|
TW201628625A
(zh)
|
2015-02-06 |
2016-08-16 |
英特賽普醫藥品公司 |
組合療法醫藥組成物
|
|
EP3256134A4
(en)
|
2015-02-11 |
2018-10-03 |
Enanta Pharmaceuticals, Inc. |
Bile acid analogs as fxr/tgr5 agonists and methods of use thereof
|
|
WO2016161003A1
(en)
|
2015-03-31 |
2016-10-06 |
Enanta Phamraceuticals, Inc. |
Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
|
|
US10894054B2
(en)
|
2015-04-07 |
2021-01-19 |
Intercept Pharmaceuticals, Inc. |
FXR agonist compositions for combination therapy
|
|
WO2016173493A1
(en)
*
|
2015-04-28 |
2016-11-03 |
Shanghai De Novo Pharmatech Co. Ltd. |
Sulfonylaminocarbonyl derivative, pharmaceutical composition and uses thereof
|
|
EP3124080A1
(en)
|
2015-07-28 |
2017-02-01 |
Merz Pharma GmbH & Co. KGaA |
Semisynthetic bile acids for injection lipolysis
|
|
CA2998876A1
(en)
|
2015-09-21 |
2017-03-30 |
Intercept Pharmaceuticals, Inc. |
Methods of promoting hepatic regeneration
|
|
AU2016325619A1
(en)
|
2015-09-24 |
2018-04-12 |
Intercept Pharmaceuticals, Inc. |
Methods and intermediates for the preparation bile acid derivatives
|
|
MA42339A1
(fr)
|
2015-10-07 |
2019-01-31 |
Intercept Pharmaceuticals Inc |
Modulateurs du récepteur farnésoïde x
|
|
IL243707A0
(en)
|
2016-01-20 |
2016-05-01 |
Galmed Res And Dev Ltd |
Treatment to regulate the microbiota in the intestine
|
|
US20200262865A1
(en)
*
|
2016-02-15 |
2020-08-20 |
Alexander Khoruts |
Compositions and methods for treating clostridium associated diseases
|
|
US20170233431A1
(en)
*
|
2016-02-17 |
2017-08-17 |
City Of Hope |
Bile acid derivatives and methods for synthesis and use
|
|
US10323060B2
(en)
|
2016-02-23 |
2019-06-18 |
Enanta Pharmaceuticals, Inc. |
Benzoic acid derivatives of bile acid as FXR/TGR5 agonists and methods of use thereof
|
|
WO2017147159A1
(en)
|
2016-02-23 |
2017-08-31 |
Enanta Pharmaceuticals, Inc. |
Deuterated bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
|
|
WO2017147174A1
(en)
|
2016-02-23 |
2017-08-31 |
Enanta Pharmaceuticals, Inc. |
Heteroaryl containing bile acid analogs as fxr/tgr5 agonists and methods of use thereof
|
|
JPWO2017170434A1
(ja)
|
2016-03-28 |
2019-01-31 |
インターセプト ファーマシューティカルズ， インコーポレイテッド |
Ｆｘｒアゴニストとａｒｂの組み合わせ医薬
|
|
WO2017180577A1
(en)
*
|
2016-04-13 |
2017-10-19 |
Intercept Pharmaceuticals, Inc. |
Methods of treating cancer
|
|
ES2929758T3
(es)
|
2016-05-05 |
2022-12-01 |
Childrens Hospital Med Ct |
Métodos para la fabricación in vitro de tejido del fondo gástrico y composiciones relacionadas con el mismo
|
|
GB201608777D0
(en)
|
2016-05-18 |
2016-06-29 |
Dextra Lab Ltd |
Compounds
|
|
GB201608776D0
(en)
|
2016-05-18 |
2016-06-29 |
Dextra Lab Ltd |
Methods and compounds
|
|
MX385718B
(es)
|
2016-06-13 |
2025-03-18 |
Gilead Sciences Inc |
Compuestos moduladores de fxr (nr1h4).
|
|
CA3252823A1
(en)
|
2016-06-13 |
2025-02-25 |
Gilead Sciences, Inc. |
Substituted tert-butyl-3-(2-chloro-phenyl)-3-hydroxyazetidine-1-carboxylate compounds
|
|
KR20190057108A
(ko)
*
|
2016-09-30 |
2019-05-27 |
인터셉트 파마슈티컬즈, 인크. |
담즙산 유도체의 결정형
|
|
KR102729404B1
(ko)
|
2016-11-04 |
2024-11-14 |
칠드런즈 호스피탈 메디칼 센터 |
간 유사 장기 조성물 및 이를 제조 및 사용하는 방법
|
|
US11197870B2
(en)
|
2016-11-10 |
2021-12-14 |
Galmed Research And Development Ltd |
Treatment for hepatic fibrosis
|
|
CN110121347A
(zh)
|
2016-11-29 |
2019-08-13 |
英安塔制药有限公司 |
制备磺酰脲胆汁酸衍生物的方法
|
|
JP7068305B2
(ja)
|
2016-12-05 |
2022-05-16 |
チルドレンズ ホスピタル メディカル センター |
結腸オルガノイドならびにその作製方法および使用方法
|
|
US10472386B2
(en)
|
2017-02-14 |
2019-11-12 |
Enanta Pharmaceuticals, Inc. |
Bile acid derivatives as FXR agonists and methods of use thereof
|
|
TW201832768A
(zh)
*
|
2017-03-07 |
2018-09-16 |
英特賽普醫藥品公司 |
治療癌症的方法
|
|
US20180256600A1
(en)
*
|
2017-03-07 |
2018-09-13 |
Intercept Pharmaceuticals, Inc. |
Methods of treating cancer
|
|
PT3600309T
(pt)
|
2017-03-28 |
2022-10-03 |
Gilead Sciences Inc |
Combinações terapêuticas para o tratamento de doenças hepáticas
|
|
WO2018178260A1
(en)
|
2017-03-30 |
2018-10-04 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for reducing persistence and expression of episomal viruses
|
|
BR112019020780A2
(pt)
|
2017-04-07 |
2020-04-28 |
Enanta Pharm Inc |
processo para preparação de derivados de ácido biliar de carbamato de sulfonila
|
|
US12281334B2
(en)
|
2017-04-14 |
2025-04-22 |
Children's Hospital Medical Center |
Multi donor stem cell compositions and methods of making same
|
|
CA3070837A1
(en)
|
2017-07-24 |
2019-01-31 |
Intercept Pharmaceuticals, Inc. |
Isotopically labeled bile acid derivatives
|
|
CA3075205A1
(en)
|
2017-09-08 |
2019-03-14 |
Mina Therapeutics Limited |
Stabilized hnf4a sarna compositions and methods of use
|
|
EP3694603B1
(en)
|
2017-10-10 |
2026-04-08 |
Children's Hospital Medical Center |
Esophageal tissue and/or organoid compositions and methods of making same
|
|
US12379372B2
(en)
|
2017-12-21 |
2025-08-05 |
Children's Hospital Medical Center |
Digitalized human organoids and methods of using same
|
|
KR102887406B1
(ko)
|
2018-07-26 |
2025-11-19 |
칠드런즈 호스피탈 메디칼 센터 |
간-담도-췌장 조직 및 이를 제조하는 방법
|
|
GB201812382D0
(en)
|
2018-07-30 |
2018-09-12 |
Nzp Uk Ltd |
Compounds
|
|
US11208571B2
(en)
|
2018-08-08 |
2021-12-28 |
University Of Maryland, College Park |
Methods for nondestructive dispersing of carbon nanomaterials in water
|
|
AU2019339410A1
(en)
|
2018-09-12 |
2021-04-15 |
Children's Hospital Medical Center |
Organoid compositions for the production of hematopoietic stem cells and derivatives thereof
|
|
EP3911647B1
(en)
|
2019-01-15 |
2023-12-13 |
Gilead Sciences, Inc. |
Isoxazole compound as fxr agonist and pharmaceutical compositions comprising same
|
|
WO2020160371A1
(en)
|
2019-02-01 |
2020-08-06 |
The University Of Hong Kong |
Innervated organoid compositions and methods of making same
|
|
WO2020163201A1
(en)
*
|
2019-02-04 |
2020-08-13 |
Intercept Pharmaceuticals, Inc. |
Treatment and prevention of intestinal inflammatory diseases with a bile acid derivative
|
|
CA3233305A1
(en)
|
2019-02-19 |
2020-08-27 |
Gilead Sciences, Inc. |
Solid forms of fxr agonists
|
|
CN114144185A
(zh)
|
2019-05-30 |
2022-03-04 |
英特塞普特医药品公司 |
用于治疗胆汁淤积性肝病的包含fxr激动剂和贝特类的药物组合物
|
|
WO2020243613A1
(en)
|
2019-05-31 |
2020-12-03 |
Children's Hospital Medical Center |
Methods of generating and expanding hematopoietic stem cells
|
|
WO2020243633A1
(en)
|
2019-05-31 |
2020-12-03 |
Children's Hospital Medical Center |
Shaped organoid compositions and methods of making same
|
|
CN112142814B
(zh)
*
|
2019-06-26 |
2021-09-28 |
江苏吉贝尔药业股份有限公司 |
牛磺熊去氧胆酸衍生物以及包含其的药物组合物和制剂
|
|
KR20220035365A
(ko)
|
2019-07-18 |
2022-03-22 |
엔요 파마 |
인터페론의 부작용을 감소시키는 방법
|
|
IL293892A
(en)
|
2020-01-15 |
2022-08-01 |
Inserm Institut National De La Sant? Et De La Rech M?Dicale |
Use of fxr agonists for treating an infection by hepatitis d virus
|
|
JP2024502673A
(ja)
|
2021-01-14 |
2024-01-22 |
ウエヌイグレックオ・ファーマ |
Ｈｂｖ感染の処置のためのｆｘｒアゴニストとｉｆｎの相乗効果
|
|
JP2024517181A
(ja)
|
2021-04-28 |
2024-04-19 |
ウエヌイグレックオ・ファーマ |
組合せ治療としてｆｘｒアゴニストを使用するｔｌｒ３アゴニストの効果の強い増強
|
|
CN119950519B
(zh)
*
|
2025-01-07 |
2025-11-21 |
山东省海洋科学研究院(青岛国家海洋科学研究中心) |
奥贝胆酸在对虾急性肝胰腺坏死病防治中的应用
|